Gland Pharma Limited will host an earnings conference call for investors and analysts on Monday, August 10, 2026, at 18:30 hours (IST). The 60-minute session is scheduled to discuss the company's financial performance and business updates for the quarter ended June 30, 2026. This communication serves as the primary channel for management to provide context on the Q1 FY27 results and address stakeholder inquiries regarding operational developments.

The notice was issued on July 24, 2026, by Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer, to both BSE Limited and the National Stock Exchange of India Limited. The filing confirms that the audio recording and transcript of the earnings call will be made available on the company's website following the event. Investors can access the call via dial-in numbers or a diamond pass link provided in the enclosure.

Earnings Call Details

The conference call is structured to allow for both management presentations and a question-and-answer segment. Participants can join using the universal access numbers or international toll-free lines provided below.

For those preferring digital access, a diamond pass link is available for registration. Post-call materials, including the full transcript and audio recording, will be hosted at www.glandpharma.com .

Contact Information

Investors seeking further information can reach out to the investor relations team. Shriniwas Pradeep Dange handles investor relations and can be contacted at investors@glandpharma.com . For corporate governance matters, Sampath Kumar Pallerlamudi remains the primary point of contact as the Company Secretary and Compliance Officer.

Gland Pharma Limited has received shareholder approval to reappoint Mr. Udo Johannes Vetter and appoint Mr. William Robert Keller as Independent Directors following a remote e-voting process. The voting, which concluded on July 18, 2026, sanctioned commissions on profits as remuneration for these directors and approved a revision of remuneration for existing Independent Director Mr. Essaji Goolam Vahanvati. These appointments strengthen the company's board governance structure for the next five years.

The postal ballot was conducted pursuant to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. D Soumya, Associate Partner at RVR & Associates, Company Secretaries, served as the Scrutinizer for the process. The remote e-voting period commenced on June 19, 2026, and members holding shares as on June 12, 2026, were eligible to participate.

Director Tenures and Profiles

Mr. Udo Johannes Vetter has been reappointed for a second term of five consecutive years, effective from July 21, 2026, to July 20, 2031. He holds a degree in Clinical Pharmacy from the University of Washington and has extensive experience, including roles at Schering-Plough Corp. and as Managing Director of Vetter Inject GmbH & Co. KG. He currently serves as Chairman of the ITM Group, Germany.

Mr. William Robert Keller has been appointed as an Independent Director for a period of five consecutive years with effect from June 15, 2026, to June 14, 2031. Aged 78, Mr. Keller brings over 40 years of experience in the pharmaceutical and biotechnology sectors, having held management positions at Roche in South America and Asia. He currently serves as an Independent Director of Wuxi Biologics and Hua Medicine.

Voting Results Summary

All five resolutions presented to the shareholders were passed with the requisite majority. The total number of votes cast across the resolutions was 14,87,41,512. The table below details the voting outcomes for each resolution.

Key Voting Breakdown

The resolution to reappoint Mr. Udo Johannes Vetter saw 86.90% of votes in favour, with Public Institutions casting 19,48,082 votes against the proposal. Conversely, the special resolution to appoint Mr. William Robert Keller received 99.11% approval, with Public Institutions recording 13,22,387 votes against it.

For the ordinary resolutions regarding remuneration, shareholder support was higher. The proposal to consider commission on profits for Mr. Vetter received 99.18% approval, while the similar resolution for Mr. Keller was passed with 99.12% votes in favour. The revision of commission for Mr. Essaji Goolam Vahanvati was approved by 99.18% of the votes polled. The Promoter and Promoter Group voted 100% in favour of all resolutions. The results were declared on July 20, 2026.